Compare Dolby Laboratories, Inc. (DLB) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Figs Inc — how do they compare? Dolby Laboratories, Inc. trades at $58.9 (market cap $5.47B), while Figs Inc trades at $14.96 (market cap $2.49B). The key difference: Dolby Laboratories, Inc. is far larger — about 2.2× Figs Inc's market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Figs Inc for 33 Days on average.
| DLB | FIGS | |
|---|---|---|
Market Cap | $5.47B | $2.49B |
Volume | 1,058,284 | 5,964,311 |
Sector | Technology | Consumer Cyclical |
52-Week High | $70.09 | $17.12 |
52-Week Low | $48.51 | $6.90 |
Typical Hold Time | 98 Days | 33 Days |
Enterprise Value | $4.85B | $2.25B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals. The company maintains strong profitability with 87.61% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten. Cash flow improved significantly in 2025 with $472M operating cash flow.
DLB presents a mixed outlook with strong fundamentals but technical weakness. The 47% upside to $90.33 consensus target offers potential, though near-term execution risks and licensing volatility remain concerns. Revenue stability around $1.3B and premium valuation metrics require continued innovation execution to justify current multiples.
FIGS trades at $14.06, down 0.28% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $556M in 2024 to $631M in 2025, with net income surging to $34M. Recent quarters have consistently beaten EPS expectations, and international sales grew 67% in Q2 2026. Analyst consensus is bullish with a $18.00 price target suggesting 28% upside potential from current levels.
The outlook remains positive with accelerating growth and margin expansion, though the stock's rich valuation (P/E 42.6) presents risk if execution falters. Key catalysts include continued international expansion and sustained demand from healthcare professionals, while risks include premium valuation pressure and competitive threats in medical apparel.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
